Gefitinib or carboplatin
WebMok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–957. 6. Shepherd FA, Rodrigues Pereira J, et al; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123–132. 7. WebGefitinib had a more favorable tolerability profile than carboplatin/paclitaxel. Efficacy by epidermal growth factor receptor biomarker status (exploratory analyses) was difficult to …
Gefitinib or carboplatin
Did you know?
WebApr 30, 2010 · Herbst RS, Giaccone G, Schiller JH, et al: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 2. J Clin Oncol 22:785-794, 2004. Financial Disclosure: Dr. Miller has received honoraria for consulting from Genentech and Roche. WebGefitinib, sold under the brand name Iressa, is a medication used for certain breast, lung and other cancers. Gefitinib is an EGFR inhibitor, like erlotinib, which interrupts signaling through the epidermal growth factor receptor (EGFR) in target cells.
WebAug 13, 2014 · No significant differences exist in terms of efficacy and survival between first-line gefitinib and paclitaxel/carboplatin for Chinese patients with pulmonary … WebIn the subgroup of 437 IPASS patients providing evaluable EGFR mutation results, gefitinib statistically significantly extended progression-free survival (PFS) compared with carboplatin and paclitaxel in EGFR M+ patients (HR 0.48, 95% CI: 0.36, 0.64; median PFS 9.5 months compared with 6.3 months).
WebEpidermal growth factor receptor; gefitinib; nonsmall cell lung cancer; personalised medicine; Lung cancer is the most common cause of cancer deaths worldwide [].Many cases are not diagnosed until the disease is at an advanced stage, and the prognosis is poor with a 5-yr survival rate of ∼15% [].Nonsmall cell lung cancer (NSCLC) accounts … WebAug 23, 2024 · A compound represented by Formula 1 according to the present disclosure, when used in combination with an anticancer drug, may significantly improve the anticancer effect of the anticancer drug, and may induce the same anticancer effect even when the anticancer drug is used in a significantly smaller amount than the conventionally used …
WebThese results merit further investigation to determine whether alternative sources of tumor DNA, such as cfDNA in serum, could be used for determining EGFR mutation status in future; currently, where a sample is available, analysis of tumor material is recommended.
WebOsimertinib is a third-generation, irreversible, oral EGFR-TKI that selectively inhibits both EGFR-TKI–sensitizing and EGFR p.Thr790Met (T790M) resistance mutations and has shown efficacy in... line out converter oreillys snp17marWebAll patients were untreated with EGFR-TKIs and received first-line gefitinib (250 mg/day) or erlotinib (150 mg/day) and were then subsequently treated with other EGFR-TKIs (gefitinib, erlotinib, afatinib, or osimertinib). Treatments after the second-line treatment were determined by the treating physician. line out converter oreillysWebNov 5, 2024 · Nakamura A, Inoue A, Morita S, et al. Phase III study comparing gefitinib monotherapy (G) to combination therapy with gefitinib, carboplatin, and pemetrexed (GCP) for untreated patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009). J Clin Oncol 2024; 36 (15 suppl): 9005. line out converter back speakersWebAug 13, 2014 · According to performance status, smoking status and gender, they were selected with dynamic equilibrium randomized method 1: 1 to receive first-line gefitinib (250 mg/d) in gefitinib arm or carboplatin/paclitaxel (carboplatin, area under the curve 5 mg × ml⁻¹ × min⁻¹, 21-day cycle; paclitaxel, 200 mg/m², 21-day cycle in chemotherapy arm. hottle insuranceWebGefitinib is superior to carboplatin–paclitaxel as an initial treatment for pulmonary adenocarcinoma among nonsmokers or former light smokers in East Asia. The pres - line out converter no remote wireWebNEJ002 study, comparing gefitinib with carboplatin (CBDCA) and paclitaxel (PTX; Taxol) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation, previously reported superiority of gefitinib over CBDCA/PTX on progression-free survival (PFS). Subsequent analysis … hottlet catalogueWebJan 10, 2024 · Random assignment was 1:1 to gefitinib 250 mg orally per day (Gef) or gefitinib 250 mg orally per day plus pemetrexed 500 mg/m 2 and carboplatin area … hottles restaurant wilkes-barre menu